Skip to content

EXTRA-PHARMA: value indication

Line	Code	2024	2025	Change	%
Total assets	20/58	€3,429,943	€3,063,645	-€366,297	-10.7%
Fixed assets	21/28	€1,807,728	€1,735,553	-€72,175	-4.0%
Tangible fixed assets	22/27	€1,807,728	€1,735,553	-€72,175	-4.0%
Land and buildings	22	€1,660,790	€1,598,073	-€62,718	-3.8%
Plant, machinery and equipment	23	€146,938	€137,480	-€9,458	-6.4%
Current assets	29/58	€1,622,215	€1,328,093	-€294,122	-18.1%
Stocks and contracts in progress	3	€524,082	€518,787	-€5,295	-1.0%
Stocks	30/36	€524,082	€518,787	-€5,295	-1.0%
Amounts receivable within one year	40/41	€248,147	€274,774	+€26,627	+10.7%
Trade receivables	40	€205,143	€215,503	+€10,360	+5.1%
Other amounts receivable	41	€43,004	€59,271	+€16,267	+37.8%
Current investments	50/53	€403,182	€372,754	-€30,429	-7.5%
Cash at bank and in hand	54/58	€446,044	€159,799	-€286,246	-64.2%
Deferred charges and accrued income	490/1	€759	€1,980	+€1,220	+161%
Total equity and liabilities	10/49	€3,429,943	€3,063,645	-€366,297	-10.7%
Equity	10/15	€477,161	€559,094	+€81,933	+17.2%
Contributions	10/11	€18,600	€18,600	=	0.0%
Reserves	13	€70,902	€70,902	=	0.0%
Distributable reserves	133	€70,902	€70,902	=	0.0%
Profit (loss) carried forward	14	€387,659	€469,592	+€81,933	+21.1%
Amounts payable	17/49	€2,952,782	€2,504,552	-€448,230	-15.2%
Amounts payable after more than one year	17	€1,952,392	€1,829,992	-€122,400	-6.3%
Financial debts	170/4	€1,952,392	€1,829,992	-€122,400	-6.3%
Amounts payable within one year	42/48	€996,053	€670,862	-€325,191	-32.6%
Current portion of amounts payable after more than one year	42	€265,808	€194,293	-€71,516	-26.9%
Financial debts	43	€32,222	€32,426	+€204	+0.6%
Credit institutions	430/8	€32,222	€32,426	+€204	+0.6%
Trade debts	44	€366,848	€368,072	+€1,224	+0.3%
Suppliers	440/4	€366,848	€368,072	+€1,224	+0.3%
Taxes, remuneration and social security	45	€55,717	€60,177	+€4,460	+8.0%
Taxes	450/3	€1,168	€13	-€1,155	-98.9%
Remuneration and social security	454/9	€54,549	€60,164	+€5,615	+10.3%
Other amounts payable	47/48	€275,458	€15,895	-€259,563	-94.2%
Accrued charges and deferred income	492/3	€4,336	€3,697	-€639	-14.7%
Non-recurring operating income	76A	-	€2,069	+€2,069
Remuneration, social security and pensions	62	€529,424	€524,774	-€4,650	-0.9%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets	630	€102,915	€104,535	+€1,619	+1.6%
Other operating charges	640/8	€5,670	€3,282	-€2,388	-42.1%
Non-recurring operating charges	66A	€9,190	-	-€9,190
Gross operating margin	9900	€896,503	€765,107	-€131,396	-14.7%
Operating profit (loss)	9901	€249,304	€132,516	-€116,788	-46.8%
Financial income	75/76B	€372,394	€54,678	-€317,716	-85.3%
Recurring financial income	75	€370,308	€52,488	-€317,820	-85.8%
Non-recurring financial income	76B	€2,087	€2,191	+€104	+5.0%
Financial charges	65/66B	€155,781	€53,176	-€102,605	-65.9%
Recurring financial charges	65	€155,781	€53,176	-€102,605	-65.9%
Profit (loss) for the period before taxes	9903	€465,917	€134,019	-€331,898	-71.2%
Income taxes	67/77	€52,848	€36,239	-€16,609	-31.4%
Profit (loss) for the period	9904	€413,070	€97,780	-€315,289	-76.3%
Profit (loss) for the period to be appropriated	9905	€413,070	€97,780	-€315,289	-76.3%

EXTRA-PHARMA: value indication

EXTRA-PHARMA: value indication

Position among the sector peers

What moved between 2024 and 2025

Largest movements

Change in the result, 2024 to 2025

Derived cash bridge

Value

Indicative value of the equity

Adjusted equity

Capitalised earnings

Your EBITDA multiple

Limits of the indication

Next steps